News for ACADIA Pharmaceuticals Inc. (ACAD)

On June 26, 2025, Oppenheimer analyst Jay Olson announced an update regarding ACADIA Pharmaceuticals (ACAD), maintaining a "Perform" rating on the stock. The ra

JMP Securities has reiterated its "Market Outperform" rating for ACADIA Pharmaceuticals (ACAD), maintaining its previous price target of $37.00 USD. The decisio

ACADIA Pharmaceuticals (ACAD) continues to receive positive attention from analysts, as evidenced by HC Wainwright & Co.'s recent reiteration of their

Federal judge blocks Trump admin from withholding EV charging funds. Tesla market share shrinks in EU, registrations drop 40% Y/Y. Cathie Wood’s Ark Invest makes major moves in Shopify.

On June 23, 2025, RBC Capital, led by analyst Brian Abrahams, announced an update on ACADIA Pharmaceuticals (ACAD). The firm has maintained its "Outperform" rat

On June 12, 2025, Baker Bros. Advisors LP executed a significant stock transaction involving Prelude Therapeutics Inc. The firm added 146,144 shares of Prelude

Summary ACADIA Pharmaceuticals Inc (ACAD) announced on June 6, 2025, that its Compensation Committee has granted inducement awards to 41 new employees under the

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

Acadia Pharmaceuticals (ACAD) grants inducement stock options and RSUs to 41 new employees. The awards, under Nasdaq Rule 5635(c)(4), include 187,664 st

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Acadia Pharmaceuticals (ACAD) has received a favorable ruling from the Federal Court of Appeals, which upholds the validity of its '740 composition of matter pa

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. Distri

Summary: Acadia Pharmaceuticals (ACAD) successfully upholds its key patent in a significant legal victory. Analysts predict a potential 21.08% upside, wi

In a recent analyst update, ACADIA Pharmaceuticals (ACAD) has received a significant price target boost from JP Morgan. The investment firm, represented by anal

JPMorgan has increased its price target for Acadia Pharmaceuticals (ACAD) from $26 to $30, maintaining an Overweight rating on the company's shares. This adjust

On June 4, 2025, Laura Brege, a Director at ACADIA Pharmaceuticals Inc (ACAD), sold 14,446 shares of the company, as reported in a SEC Filing. Following this tr

Summary ACADIA Pharmaceuticals Inc (ACAD) has announced its participation in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, sche

Acadia Pharmaceuticals (ACAD) appoints Allyson McMillan-Youngblood as Senior Vice President of Rare Disease Franchise. Allyson brings over 20 years of e

In a recent development, ACADIA Pharmaceuticals, known by its stock ticker ACAD, has seen a significant upgrade from Deutsche Bank. The financial services firm